Gene therapy for neurodegenerative disorders

Abstract

Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.

1 . A self-complementary adeno-associated virus (scAAV) vector comprising a polynucleotide encoding a protein that modulates motor function in a subject with a motor neuron disorder. 
     
     
         2 . The scAAV vector of  claim 1 , wherein the motor neuron disorder is selected from spinal muscular atrophy (SMA), amytrophic lateral sclerosis (ALS), spinal bulbar muscular atrophy, spinal cerebellar ataxia, primary lateral sclerosis (PLS), or traumatic spinal cord injury. 
     
     
         3 . The scAAV vector of  claim 2 , wherein the motor neuron disorder is SMA. 
     
     
         4 . The scAAV vector of  claim 3 , wherein the polynucleotide encodes a survival motor neuron (SMN) protein. 
     
     
         5 . The scAAV vector of  claim 4 , wherein the SMN protein is encoded by human SMN-1. 
     
     
         6 . The scAAV vector of  claim 5 , wherein the SMN protein comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO:2. 
     
     
         7 . The scAAV vector of  claim 6 , wherein the SMN protein comprises an amino acid sequence of SEQ ID NO:2. 
     
     
         8 . A recombinant AAV virion, comprising the scAAV vector of  claim 1 . 
     
     
         9 . A composition comprising a recombinant AAV virion according to  claim 8  and a pharmaceutically acceptable excipient. 
     
     
         10 . A method of modulating motor function in a subject with a motor neuron disorder comprising administering a therapeutically effective amount of the composition of  claim 9  to cells of the subject. 
     
     
         11 . A method of providing SMN protein to a subject with spinal muscular atrophy (SMA) comprising administering a recombinant AAV virion comprising an AAV vector according to  claim 4  to cells of a subject in need thereof. 
     
     
         12 . The method of  claim 10 , wherein the composition is administered via administration into at least one region of the deep cerebellar nuclei of the cerebellum. 
     
     
         13 . The method of  claim 10 , wherein the composition is administered via direct spinal cord injection. 
     
     
         14 . The method of  claim 10 , wherein the composition is administered via intracerebroventricular injection 
     
     
         15 . The method of  claim 14 , wherein the composition is administered into at least one cerebral lateral ventricle. 
     
     
         16 . The method of  claim 10 , wherein the composition is administered via both intracerebroventricular injection and direct spinal cord injection. 
     
     
         17 . The method of  claim 10 , wherein the composition is administered via intrathecal injection. 
     
     
         18 - 19 . (canceled) 
     
     
         20 . The method of  claim 11 , wherein the composition is administered via administration into at least one region of the deep cerebellar nuclei of the cerebellum. 
     
     
         21 . The method of  claim 11 , wherein the composition is administered via direct spinal cord injection. 
     
     
         22 . The method of  claim 11 , wherein the composition is administered via intracerebroventricular injection 
     
     
         23 . The method of  claim 22 , wherein the composition is administered into at least one cerebral lateral ventricle. 
     
     
         24 . The method of  claim 11 , wherein the composition is administered via both intracerebroventricular injection and direct spinal cord injection. 
     
     
         25 . The method of  claim 11 , wherein the composition is administered via intrathecal injection.